Siemens Healthineers expands buyback: Siemens Healthineers stock sits 14.97 percent below its high

Published on 10/27/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue hit EUR 5.764 billion, up 2.80 percent. Siemens Healthineers stock costs EUR 42.26 on October 27, 2026 versus EUR 42.29 Xetra close.

Share repurchases and report dates

Siemens Healthineers bought back 50,000 shares between October 19 and October 25, 2026.
Third-quarter 2026 revenue reached EUR 5.764 billion with 2.80 percent comparable growth.
Siemens Healthineers stock was trading at EUR 42.26 at 11:20 a.m. CEST on October 27, 2026, 0.07 percent below the Xetra close of October 26, 2026.
Fourth-quarter and fiscal 2026 results are scheduled for November 5, 2026.

Siemens Healthineers, DE000SHL1006, Illustration mit AI erstellt.

Siemens Healthineers (ISIN DE000SHL1006) was trading at EUR 42.26 at Lang & Schwarz on October 27, 2026, at 11:20 a.m. CEST, 0.07 percent below the Xetra close of October 26, 2026 at EUR 42.29. The latest buyback disclosure gives investors a concrete signal ahead of the group's fourth-quarter report.

Siemens Healthineers bought back 50,000 shares between October 19 and October 25, 2026, taking the cumulative volume since June 1 to 3,579,346 shares, according to FinanzNachrichten on October 26, 2026.

Three buyback milestones

The chronology shows a steady repurchase program. Siemens Healthineers disclosed 50,000 shares bought between October 5 and October 9, 2026, on October 12, 2026, according to EQS News. A further 55,000 shares were acquired between October 12 and October 18, 2026, as reported on October 19, 2026, followed by the latest 50,000-share tranche through October 25, 2026, according to FinanzNachrichten.

Q3 growth faces a mixed picture

Siemens Healthineers reported EUR 5.764 billion of revenue in the third quarter of fiscal 2026, with comparable growth of 2.80 percent. Adjusted EBIT margin was 19.10 percent, while the company said the margin was 15.40 percent excluding tariff refunds. The figures and the fiscal 2026 outlook were discussed in the company's Q3 materials and earnings call on July 31, 2026, available through Siemens Healthineers.

The comparison matters because the fiscal 2026 outlook calls for comparable revenue growth of 3.50 to 4.00 percent, while adjusted earnings per share are guided to EUR 2.35 to EUR 2.45. Diagnostics remains the pressure point, whereas Imaging and Precision Therapy are expected to accelerate in the fourth quarter.

What does the buyback mean for valuation?

The repurchases are taking place while the stock sits 14.97 percent below its 52-week high of EUR 49.70. Market capitalization stands at EUR 47.3 billion as of October 27, 2026, giving the program a visible but measured role against the company's overall equity value.

Two dates for investors

The next reporting date is November 5, 2026, when Siemens Healthineers is scheduled to publish fourth-quarter and fiscal 2026 results and hold its analyst call. The company also lists a US roadshow for November 6, 2026, according to its investor-relations calendar.

Stock trades below its yearly high

RBC raised its price target from EUR 45.00 to EUR 48.00 and kept an Outperform rating on October 15, 2026, citing the Accela radiation therapy system, according to MarketScreener. The target is EUR 5.74 above the current Lang & Schwarz price.

Siemens Healthineers was trading at EUR 42.26 at Lang & Schwarz on October 27, 2026, at 11:20 a.m. CEST, 0.07 percent below the Xetra close of October 26, 2026 at EUR 42.29. The further course of trading is shown by the continuously updated real-time quote of Siemens Healthineers stock.